These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18421055)

  • 1. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
    J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
    Efficace F; Bottomley A; Coens C; Van Steen K; Conroy T; Schöffski P; Schmoll H; Van Cutsem E; Köhne CH
    Eur J Cancer; 2006 Jan; 42(1):42-9. PubMed ID: 16298522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
    Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
    J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
    Efficace F; Therasse P; Piccart MJ; Coens C; van Steen K; Welnicka-Jaskiewicz M; Cufer T; Dyczka J; Lichinitser M; Shepherd L; de Haes H; Sprangers MA; Bottomley A
    J Clin Oncol; 2004 Aug; 22(16):3381-8. PubMed ID: 15310784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
    Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman RE; Calvert HA; Gamucci T; Twelves C; Fargeot P; Bottomley A;
    Eur J Cancer; 2004 May; 40(7):1021-30. PubMed ID: 15093577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
    Grande GE; Farquhar MC; Barclay SI; Todd CJ
    Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
    Mormont MC; Waterhouse J; Bleuzen P; Giacchetti S; Jami A; Bogdan A; Lellouch J; Misset JL; Touitou Y; Lévi F
    Clin Cancer Res; 2000 Aug; 6(8):3038-45. PubMed ID: 10955782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.
    Meyer F; Fortin A; Gélinas M; Nabid A; Brochet F; Têtu B; Bairati I
    J Clin Oncol; 2009 Jun; 27(18):2970-6. PubMed ID: 19451440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
    Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
    Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet.
    Comella P; Casaretti R; Manzo R; Sandomenico C; Licenziato M; Avallone A; Franco L;
    Acta Oncol; 2010; 49(1):50-6. PubMed ID: 20100144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
    Jantscheff P; Terracciano L; Lowy A; Glatz-Krieger K; Grunert F; Micheel B; Brümmer J; Laffer U; Metzger U; Herrmann R; Rochlitz C
    J Clin Oncol; 2003 Oct; 21(19):3638-46. PubMed ID: 14512395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
    Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ
    J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
    Mauer ME; Taphoorn MJ; Bottomley A; Coens C; Efficace F; Sanson M; Brandes AA; van der Rijt CC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ;
    J Clin Oncol; 2007 Dec; 25(36):5731-7. PubMed ID: 18089867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
    Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
    J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
    Collette L; van Andel G; Bottomley A; Oosterhof GO; Albrecht W; de Reijke TM; Fossà SD
    J Clin Oncol; 2004 Oct; 22(19):3877-85. PubMed ID: 15459209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.